Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)
Condition: Lung Cancer Intervention: Other: Non-interventional Sponsor: Bristol-Myers Squibb Active, not recruiting
Objective: To determine whether surgery with adjuvant chemotherapy offers a survival advantage over concurrent chemoradiation for patients with cT1-2N0M0 small cell lung cancer (SCLC). Background: Although surgery with adjuvant chemotherapy is the recommended treatment for patients with cT1-2N0M0 SCLC per international guidelines, there have been no prospective or retrospective studies evaluating the impact of surgery versus optimal medical management for cT1-2N0M0 SCLC. Methods: Outcomes of patients with cT1-2N0M0 SCLC who underwent surgery with adjuvant chemotherapy or concurrent chemoradiation in the National Ca...
Authors: Jiang W, Meng L, Xu G, Lv C, Wang H, Tian H, Chen R, Jiao B, Wang B, Huang C Abstract Wentilactone A (WA), a marine-derived compound, inhibits proliferation of NCI-H446, as demonstrated by previous research; however, the anti-SCLC mechanism underlying WA was not fully investigated. The present study aimed to investigate the anti-SCLC mechanism underlying WA in vitro and in vivo. Cell Counting Kit-8 was used to assay cell growth, flow cytometry was conducted to analyze cell apoptosis and nude mice xenografts were used to examine SCLC growth following WA treatment. Bioinformatics was used for verification of...
ConclusionThe integrated bioinformatical analysis could improve our understanding of the underlying molecular mechanism about how aspirin working in SCLC. Integrated bioinformatical analysis may be considered as a new paradigm for guiding future studies about interaction in drugs and diseases.Graphical abstract
Approximately 234,030 new cases of lung cancer will be diagnosed in 2018, ~14% of which will be small cell lung cancer (SCLC) [1 –3]. SCLC is traditionally staged using the Veterans Affairs Lung Study Group staging system, which divides SCLC patients largely based on the size and spread of the tumor into 1 of 2 stages: limited-stage disease or extensive-stage (ES) disease [4–7]. SCLC presents with an aggressive clinical c ourse, frequently with widespread metastases at diagnosis and, as such, approximately two-thirds of patients have ES disease at diagnosis .
Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneoplastic disorders and controls.SOX2 antibodies were detectable in 61% of patients with LEMS-SCLC, and in other paraneoplastic disorders, such as opsoclonus-myoclonus and paraneoplastic cerebellar degeneration, only when there was an underlying SCLC.
The antitumor action of etoposide is due to inhibition of DNA topoisomerase II and the consequent introduction of strand breaks into DNA . Combination therapies with etoposide and a platinum agent (cisplatin or carboplatin) are the standard of care for patients with small cell lung cancer (SCLC) [2 –6], but some treated individuals experience serious hematologic or nonhematologic toxicities including nephrotoxicity. Predictive factors for adverse events of platinum-etoposide doublet therapy for SCLC have not been identified to date, however.
Conclusions We demonstrate a significant overlapping similarity of protein expression profiles of lung and cervical small cell carcinomas despite the significant differences in their organs of origin.
In conclusion, PCI might be suggested for limited SCLC patients who received definitive surgery.
(International Association for the Study of Lung Cancer) Elderly patients with limited-stage small cell lung cancer (LS-SCLC) showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy. Concurrent chemo-radiotherapy should be a treatment option for fit patients aged 70 years or older.
ConclusionA combination of carboplatin plus paclitaxel as second-line chemotherapy is effective and feasible in patients with SCLC, especially in those with ILD.